Human VEGF-C Quantikine ELISA Kit

Product Details

Summary
Reactivity HuSpecies Glossary
Applications ELISA
Conjugate
HRP

Order Details

Human VEGF-C Quantikine ELISA Kit Summary

Background
The Quantikine Human VEGF-C Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human VEGF-C in cell culture supernates, serum, plasma, and saliva. It contains NS0-expressed recombinant human VEGF-C (Cys156Ser substituted) and has been shown to accurately quantitate the recombinant factor. Results obtained using recombinant human VEGF-C (wild type) and natural human VEGF-C showed... linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring human VEGF-C.
Show More
Specificity
Natural human VEGF-C, recombinant human VEGF-C (wild type), and recombinant human VEGF-C (Cys156Ser substituted)
Assay Type
Solid Phase Sandwich ELISA
Inter-Assay
See PDF Datasheet for details
Intra-Assay
See PDF Datasheet for details
Spike Recovery
See PDF Datasheet for details
Sample Volume
See PDF Datasheet for details
Gene
VEGFC

Applications/Dilutions

Dilutions
  • ELISA
Application Notes
No significant interference observed with available related molecules.
Publications
Read Publications using DVEC00.

Packaging, Storage & Formulations

Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human VEGF-C Quantikine ELISA Kit

  • Flt4 ligand
  • Flt4-L
  • vascular endothelial growth factor C
  • Vascular endothelial growth factor-related protein
  • VEGFC
  • VEGF-C
  • VRPFLT4 ligand DHM

Background

Vascular endothelial growth factor C (VEGF-C) is a homodimeric ligand of VEGF R3/Flt-4 and is synthesized with N- and C-terminal propeptides. Fully processed VEGF-C containing only the VEGF homology domain can additionally bind and activate VEGF R2/KDR/Flk-1. VEGF-C interactions with VEGF R3 are critical for lymphangiogenesis. Both the ligand and receptor are usually co-expressed at sites of lymphatic vessel sprouting, in the embryo, and in various pathological conditions. Over-expression of VEGF-C in tumor cells induces tumoral lymphatic hyperplasia, neoangiogenesis, and vessel sprouting, resulting in enhanced lymph flow and metastasis to regional lymph nodes.

Customers Who Viewed This Item Also Viewed...

DVE00
Species: Hu
Applications: ELISA
DVED00
Species: Hu
Applications: ELISA
AF743
Species: Mu
Applications: CyTOF-ready, Flow, WB
AF2125
Species: Mu
Applications: IHC, WB
AF644
Species: Mu
Applications: CyTOF-ready, Flow, IHC, Neut, WB
AF321
Species: Hu
Applications: Block, CyTOF-ready, Flow, IHC, WB
AF3244
Species: Mu
Applications: IHC, WB
NB100-689
Species: Hu, Rt
Applications: IHC, IHC-Fr, IHC-P, Simple Western, WB
DPG00
Species: Hu
Applications: ELISA
233-FB/CF
Species: Hu
Applications: BA
AF751
Species: Hu
Applications: WB
AF3628
Species: Mu, Rt
Applications: CyTOF-ready, Flow, ICC, IHC, WB
NB110-41083
Species: Hu
Applications: ChIP, ELISA, ICC/IF, WB
NB600-1071
Species: Hu(-), Mu
Applications: ELISA, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
NBP1-33050
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
DVEC00
Species: Hu
Applications: ELISA
⚠ WARNING: This product can expose you to chemicals including N,N-Dimethylforamide, which is known to the State of California to cause cancer. For more information, go to www.P65Warnings.ca.gov.

Publications for VEGF-C (DVEC00)(45)

We have publications tested in 2 confirmed species: Human, Mouse.


Filter By Application
All Applications
Filter By Species
Human
(42)
Mouse
(3)
All Species
Showing Publications 1 - 10 of 45. Show All 45 Publications.
Publications using DVEC00 Applications Species
IS Miller, S Khan, LP Shiels, S Das, AC O' Farrell, K Connor, A Lafferty, B Moran, C Isella, P Loadman, E Conroy, S Cohrs, R Schibli, RS Kerbel, WM Gallagher, E Marangoni, K Bennett, DP O' Connor, RM Dwyer, AT Byrne Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects Cancer Medicine, 2022;0(0):. 2022 [PMID: 35434898] (Human) Human
Y Li, C Liu, X Zhang, X Huang, S Liang, F Xing, H Tian CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt/beta-catenin signalling pathway British Journal of Cancer, 2022;0(0):. 2022 [PMID: 35194191] (Human) Human
I Wada, S Nakao, M Yamaguchi, Y Kaizu, M Arima, S Sawa, KH Sonoda Retinal VEGF-A Overexpression Is Not Sufficient to Induce Lymphangiogenesis Regardless of VEGF-C Upregulation and Lyve1+ Macrophage Infiltration Investigative Ophthalmology & Visual Science, 2021;62(13):17. 2021 [PMID: 34673901] (Human) Human
T Mashima, T Wakatsuki, N Kawata, MK Jang, A Nagamori, H Yoshida, K Nakamura, T Migita, H Seimiya, K Yamaguchi Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo Scientific Reports, 2021;11(1):15125. 2021 [PMID: 34302038] (Mouse) Mouse
M Sevinc, NB Hasbal, T Basturk, PN Ozcafer, BB Kocas, K Kilickesme, A Ozel, T Sakaci, E Ahbap, A Unsal, Y Koc Comparison of lung ultrasound and other volumetric methods in peritoneal dialysis patients Medicine, 2021;100(3):e23856. 2021 [PMID: 33545952] (Human) Human
WN Li, KY Hsiao, CA Wang, N Chang, PL Hsu, CH Sun, SR Wu, MH Wu, SJ Tsai Extracellular vesicle-associated VEGF-C promotes lymphangiogenesis and immune cells infiltration in endometriosis Proc Natl Acad Sci U S A, 2020;0(0):. 2020 [PMID: 33004630] (Human) Human
C Reglero, V Lafarga, V Rivas, Á Albitre, P Ramos, SR Berciano, O Tapia, ML Martínez-C, F Mayor, P Penela GRK2-Dependent HuR Phosphorylation Regulates HIF1&alpha Activation under Hypoxia or Adrenergic Stress Cancers (Basel), 2020;12(5):. 2020 [PMID: 32413989] (Human) Human
AZ Dudek, LC Liu, S Gupta, TF Logan, EA Singer, M Joshi, YN Zakharia, JM Lang, JK Schwarz, A Al-Janadi, AS Alva Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003 J. Clin. Oncol., 2020;38(11):1138-1145. 2020 [PMID: 32097091] (Human) Human
SK Jha, K Rauniyar, E Chronowska, K Mattonet, EW Maina, H Koistinen, UH Stenman, K Alitalo, M Jeltsch KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D Elife, 2019;8(0):. 2019 [PMID: 31099754] (Human) Human
R Wang, T Yamada, S Arai, K Fukuda, H Taniguchi, A Tanimoto, A Nishiyama, S Takeuchi, K Yamashita, K Ohtsubo, J Matsui, N Onoda, E Hirata, S Taira, S Yano Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice Mol. Cancer Ther., 2019;18(5):947-956. 2019 [PMID: 30926637] (Human) Human
Show All 45 Publications.

Reviews for VEGF-C (DVEC00) (0)

There are no reviews for VEGF-C (DVEC00). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

Product General Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for VEGF-C (DVEC00). (Showing 1 - 1 of 1 FAQs).

  1. I was wondering if you know of any blocking antibodies against IL-6 or VEGF-C that can be used in cell culture to quench these cytokines?
    • We have no antibodies that are currently known to show blocking antibodies to VEGF-C. Please see this link to our IL-6 antibodies with blocking/neutralizing activity can be found at this link.

Customers Who Bought This Also Bought

VEGF-C Antibody
NB110-61022

Contact Information

Product PDFs

Review this Product

Be the first to review our Human VEGF-C Quantikine ELISA Kit and receive a gift card or discount.

Bioinformatics

Gene Symbol VEGFC